BSECompany Update12 Oct 2026 · 12 Oct 2026, 07:51 pm
General updates
Cohance Lifesciences Ltd · 543064
✦ AI SummaryMgmt Change
Cohance Lifesciences Ltd has received Central Government approval for the appointment of Mr. Umang Vohra as Chairman and Group CEO.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Cohance Lifesciences Ltd - 543064 - General Updates
Attachments (1)
📄pdf
Download →
9219de8e-2eaf-44b0-b50c-c9984e2fa122.pdf
View document text
9 October 2026
BSE Limited National Stock Exchange of India Limited
25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051
Scrip Code: 543064 Scrip Symbol: COHANCE
Dear Sir/Madam,
Sub: Intimation regarding receipt of Central Government approval for appointment of Mr. Umang
Vohra as Chairman and Group CEO of the Company
In continuation of our letters dated 27 April 2026 and 26 June 2026 regarding appointment of Mr. Umang
Vohra (DIN: 02296740) as Chairman and Group CEO of the Company, we wish to inform you that the
Ministry of Corporate Affairs (Central Government) vide its letter dated 8 October 2026 (received by the
Company on 12 October 2026) has approved the said appointment.
This is for your information and records.
Thanking you
Yours faithfully,
For Cohance Lifesciences Limited
(formerly, Suven Pharmaceuticals Limited)
Sisir K. Mishra
Company Secretary & Compliance Officer